A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

LESSONS LEARNED. Itacitinib in combination with nab‐paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of itacitinib as a component of combination regimens...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Beatty, Gregory L., Shahda, Safi, Beck, Thaddeus, Uppal, Nikhil, Cohen, Steven J., Donehower, Ross, Gabayan, Afshin Eli, Assad, Albert, Switzky, Julie, Zhen, Huiling, Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324630/
https://ncbi.nlm.nih.gov/pubmed/30115734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0665
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados